Immatics N.V. (IMTX) 今天备受关注，此前该公司在 ASCO 年会上公布了其 IMA401（一种靶向 MAGEA4/8 的 TCR 双特异性抗体）的 1 期临床试验的鼓舞人心的数据。由于投资者消化了这一消息，该股上涨了 0.52%。这些数据同时发表在《*Nature Medicine*》上，突出了 IMA401 在治疗接受过大量预处理的实体瘤患者（包括头颈癌和肺癌）方面的潜力。
Immatics公布积极的癌症试验数据，IMTX上涨0.52%
Immatics N.V. (IMTX) 今天备受关注，此前该公司在 ASCO 年会上公布了其 IMA401（一种靶向 MAGEA4/8 的 TCR 双特异性抗体）的 1 期临床试验的鼓舞人心的数据。由于投资者消化了这一消息，该股上涨了 0.52%。
常见问题
What is IMA401 and what does it treat?
IMA401 is a TCR bispecific developed by Immatics (IMTX) targeting MAGEA4/8, a protein found on certain cancer cells. The Phase 1 trial data suggests it shows promise in treating solid tumors, including head and neck and lung cancers, even in heavily pretreated patients. The data was presented at the ASCO Annual Meeting and published in *Nature Medicine*.
How is the Immatics stock (IMTX) performing?
As of the article's publication, Immatics (IMTX) stock is up 0.52% following the positive Phase 1 clinical trial data for IMA401. Investors are reacting positively to the news, which highlights the potential of IMA401 in treating various solid tumors. The stock's performance reflects the market's optimism regarding the company's progress in oncology.